Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). 

The Company's lead initiative is the development of HspE7, a therapeutic vaccine for the possible treatment of patients with cervical dysplasia, recurrent respiratory papillomatosis and genital warts.  Headquartered in San Diego, CA, Nventa Common Stock trades on the Toronto Stock Exchange (TSX) under the symbol: NVN.

Corporate Fact Sheet (PDF)

Insight to Impact™, the Company's tagline introduced in June of 2006, communicates its mission of applying scientific insight to discover novel drugs that have a direct impact on patients suffering from difficult-to-treat diseases with few treatment options.

May 7 2008:
Nventa Appoints John Varian To Board Of Directors

April 24 2008:
Nventa Completes Safety Evaluation On Final Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial

March 26 2008:
Nventa Announces Positive Interim Immunological Data From HSPE7 Phase 1 Cervical Dysplasia Trial

March 13 2008:
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results